The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2023 | Cinrebafusp alfa with ramucirumab and paclitaxel in HER+ GEJ cancer
Geoffrey Ku, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses findings from a Phase II trial (NCT05190445) of cinrebafusp alfa, a bispecific fusion protein targeting HER2 and 4-1BB, in patients with HER2-positive gastric/gastroesophageal junction (GEJ) adenocarcinoma. The investigational drug was administered with ramucirumab and paclitaxel, and was well tolerated in patients, where a manageable safety profile was reported. All patients additionally achieved a partial response rate. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
